M159 M159 (Didanosine Delayed Release 125 mg)
Pill with imprint M159 M159 is White, Capsule-shape and has been identified as Didanosine Delayed Release 125 mg. It is supplied by Mylan Pharmaceuticals Inc..
Didanosine is used in the treatment of nonoccupational exposure; hiv infection and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). There is no proven risk in humans during pregnancy. Didanosine 125 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for M159 M159
Didanosine Delayed Release
- Imprint
- M159 M159
- Strength
- 125 mg
- Color
- White
- Size
- 18.00 mm
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Nucleoside reverse transcriptase inhibitors (nrtis)
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC)
- 00378-8886
- Inactive Ingredients
-
ferrosoferric oxide,
carboxymethylcellulose sodium,
silicon dioxide,
diethyl phthalate,
gelatin,
hypromelloses,
methacrylic acid - methyl methacrylate copolymer (1:1),
propylene glycol,
shellac,
trisodium citrate dihydrate,
sodium lauryl sulfate,
sodium starch glycolate type A potato,
magnesium silicate,
titanium dioxide,
potassium hydroxide,
ammonia
Note: Inactive ingredients may vary.
Related Images for "M159 M159"
More about didanosine
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- En Español
- Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)
- FDA Alerts (2)
Consumer resources
- Patient Information
- Didanosine (Advanced Reading)
- Didanosine Delayed-Release Enteric-Coated Capsules
- Didanosine Oral Solution
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.